Caribou Biosciences, Inc. — FY 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023, compared with FY 2022. This is an annual report; the supplied filing text does not provide a separate fourth-quarter financial statement summary. Caribou is a clinical-stage genome-editing biotechnology company with no approved products or product-sale revenue.
Financial results and liquidity
| Metric | FY 2023 / Dec. 31, 2023 | FY 2022 / Dec. 31, 2022 |
|---|---|---|
| Licensing and collaboration revenue | $34.5 million | $13.9 million |
| Research and development expense | $112.1 million | $82.2 million |
| General and administrative expense | $38.5 million | $38.0 million |
| Operating loss | $116.1 million | $106.4 million |
| Net loss | $102.1 million | $99.4 million |
| Net loss per share, basic and diluted | $1.38 | $1.64 |
| Cash used in operating activities | $93.3 million | $91.0 million |
| Cash, cash equivalents and marketable securities | $372.4 million | $317.0 million |
- Revenue is entirely from licensing and collaboration arrangements, not product sales. FY 2023 included $24.8 million from AbbVie; $20.8 million of previously deferred revenue was recognized after AbbVie’s agreement termination.
- Operating expenses were $150.5 million against $34.5 million of revenue. The filing does not present a gross margin; the company remains loss-making.
- R&D represented the largest expense. Its increase reflected higher clinical-trial and manufacturing activity, CRO/CMO costs, personnel and facilities.
- Cash flow from investing activities was negative $68.2 million, largely reflecting purchases of marketable securities and property and equipment. Financing activities provided $154.3 million, including $134.4 million net from a follow-on offering and $17.3 million net proceeds recorded for the Pfizer private placement.
- The balance sheet reported $338.8 million of current assets and $28.3 million of current liabilities. No debt is listed in the supplied balance sheet; the filing says it had no current material financing commitments other than leases and certain license-related payments.
- Lease payment obligations totaled $41.7 million, including $3.5 million due within 12 months. Management expected available cash and securities to fund the current operating plan for at least 12 months from the financial-statement issuance date.
Material changes and business developments
- Revenue rose $20.6 million year over year, primarily because of the AbbVie agreement and deferred-revenue recognition following its termination, effective October 25, 2023. This revenue source is not a dependable indicator of recurring product revenue.
- R&D expense increased $29.8 million, while G&A was broadly unchanged. Net loss increased by $2.6 million.
- Caribou raised capital through a July–August 2023 follow-on offering and Pfizer’s $25.0 million gross equity investment. Pfizer-related proceeds are restricted for BCMA-program development for 36 months, and Pfizer has information rights and a right of first negotiation on certain BCMA program transactions.
- AbbVie terminated its collaboration agreement in October 2023. Caribou also paused CB-020, its ROR-1-targeted CAR-NK candidate, as part of portfolio prioritization.
Pipeline, outlook and key risks
- CB-010: In the ANTLER Phase 1 trial, 16 dose-escalation patients had a reported 94% overall response rate and 69% complete response rate. Seven patients had a complete response at six months or later. The company reported no grade 3 or higher cytokine release syndrome and no graft-versus-host disease; severe cytopenias were among common adverse events. These are early clinical data, with follow-up ongoing. Dose expansion in second-line large B-cell lymphoma was underway. Management planned initial expansion data and an updated pivotal Phase 3 timeline for Q2 2024. FDA feedback indicated the proposed Phase 3 comparator was acceptable; this is not a guarantee of approval or trial success.
- CB-011: In the CaMMouflage Phase 1 trial for relapsed/refractory multiple myeloma, dose levels 1 and 2, three patients each, cleared without observed dose-limiting toxicities; enrollment at dose level 3 was underway. Initial dose-escalation data were planned by year-end 2024.
- CB-012: The first patient had been dosed in the AMpLify Phase 1 trial for relapsed/refractory AML; the trial was enrolling at its starting dose. No clinical efficacy results were reported in the supplied text.
- Management expects continued operating losses and substantial spending as clinical trials advance. The company states it will require additional capital in the future; funding, trial costs and timelines, and eventual profitability remain uncertain.
- Principal risks include clinical efficacy and safety, patient enrollment, regulatory requirements for novel genome-edited cell therapies, manufacturing and single-source supplier reliance, competition, and the need for additional financing. The company also faces CRISPR patent challenges and uncertainty around foundational CRISPR-Cas9 licensing revenue.
- A federal securities class action concerning disclosures about CB-010’s durability and prospects remained pending; a motion to dismiss was scheduled for argument in April 2024. A substantially similar California state case was dismissed on February 28, 2024. The filing does not state a clear estimate of potential loss for the pending case.
Most important facts for investors to verify
- Whether CB-010 dose-expansion results support the selected dose and a credible pivotal-trial plan, including response durability and safety in the intended second-line population.
- Whether planned CB-011 and CB-012 trial milestones were achieved, and what mature safety and efficacy data show.
- How quickly cash and marketable securities are being consumed relative to the stated operating-plan runway, and whether further financing or dilution is likely.
- How much future licensing revenue is recurring versus dependent on one-time or terminated collaborations, particularly AbbVie.
- Developments in the pending federal securities litigation, CRISPR intellectual-property proceedings, and the company’s ability to maintain key licenses and manufacturing supply.